Negativización de PCR a SARS-CoV-2 en muestra respiratoria en pacientes con necesidad de asistencia recurrente

Bassets-Bosch et al., Anales de Pediatría, doi:10.1016/j.anpedi.2021.01.006, Apr 2022
Time to viral- 29% improvement lower risk ← → higher risk HCQ  Bassets-Bosch et al.  LATE TREATMENT Is late treatment with HCQ + AZ beneficial for COVID-19? Retrospective 15 patients in Spain (March - April 2020) Faster viral clearance with HCQ + AZ (not stat. sig., p=0.45) c19early.org Bassets-Bosch et al., Anales de Pediat.., Apr 2022 0 0.5 1 1.5 2+ RR
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols combine treatments.
6,200+ studies for 200+ treatments. c19early.org
Retrospective 15 pediatric patients in Spain, showing faster viral clearance with HCQ+AZ, without statistical significance. Treatment time and details are not provided.
time to viral-, 29.2% lower, relative time 0.71, p = 0.45, treatment median 17.0 IQR 16.0 n=5, control median 24.0 IQR 21.0 n=5, onset to clearance.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bassets-Bosch et al., 30 Apr 2022, retrospective, Spain, peer-reviewed, 5 authors, study period 11 March, 2020 - 30 April, 2020, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary. Contact: cristinalarrosaespinosa@gmail.com, segonzalez@vhebron.net, sgonzalezperis@gmail.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 Spain United Kingdom Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Georgia Switzerland Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR Spain favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 Spain United Kingdom Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Georgia Switzerland Bosnia-Herzegovina Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria Spain favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Abstract: Anales de Pediatría 96 (2022) 350---371 Figura 1 A) Imagen de dermatoscopia: lesión seudovascular. B) Lesión cupuliforme, irregular, de coloración eritematosa viva. Bibliografía 1. Stefanaki C, Chardalias L, Soura E, Katsarou A, Stratigos A. Paediatric melanoma. J Eur Acad Dermatology Venereol. 2017;31:1604---15. 2. Merkel EA, Mohan LS, Shi K, Panah E, Zhang B, Gerami P. Paediatric melanoma: clinical update, genetic basis, and advances in diagnosis. Lancet Child Adolesc Heal. 2019;3:646---54, http://dx.doi.org/10.1016/S2352-4642(19)30116-6. 3. Lu C, Zhang J, Nagahawatte P, Easton J, Lee S, Liu Z, et al. The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol. 2015;135:816---23, http://dx.doi.org/10.1038/jid.2014.425. 4. Requena C, Rubio L, Traves V, Sanmartín O, Nagore E, Llombart B, et al. Fluorescence in situ hybridization for the differential diagnosis between Spitz naevus and spitzoid melanoma. Histopathology. 2012;61:899---909. 5. Wiesner T, Kutzner H, Cerroni L, Jr MJM, Klaus J, Murali R, et al. Genomic aberrations in spitzoid tumours and their implications for diagnosis, prognosis and therapy. 2017;48:113---31. 6. Stefanaki C, Stefanaki K, Antoniou C, Argyrakos T, Patereli A, Stratigos A, et al. Cell cycle and apoptosis regulators in Spitz Negativización de PCR a SARS-CoV-2 en muestra respiratoria en pacientes con necesidad de asistencia recurrente SARS-CoV-2 PCR negativization in respiratory sample in patients with need for recurring assistance Sra. Editora: Además de las consecuencias en términos de morbimortalidad (especialmente en pacientes adultos), la pandemia de nevi: Comparison with melanomas and common nevi. J Am Acad Dermatol. 2007;56:815---24. Cristina Larrosa a,∗ , Antonio Torrelo b , Luis Madero a y Álvaro Lassaletta a a Unidad de Onco-Hematología Pediátrica y Trasplante de Progenitores Hematopoyéticos, Hospital Universitario Niño Jesús, Madrid, España b Unidad de Dermatología, Hospital Universitario Niño Jesús, Madrid, España ∗ Autor para correspondencia. Correo electrónico: cristinalarrosaespinosa@gmail.com (C. Larrosa). https://doi.org/10.1016/j.anpedi.2021.01.008 1695-4033/ © 2021 Publicado por Elsevier España, S.L.U. en nombre de Asociación Española de Pediatrı́a. Este es un artı́culo Open Access bajo la licencia CC BY-NC-ND (http:// creativecommons.org/licenses/by-nc-nd/4.0/). SARS-CoV-2/COVID-19 ha amenazado con bloquear los circuitos asistenciales habituales. En este sentido, la detección de SARS-CoV-2 en pacientes con necesidad de contacto reiterado con el sistema sanitario ha obligado a establecer estrategias seguras de control clínico y de negativización. Se analizaron los datos de los pacientes diagnosticados de infección por SARS-CoV-2 mediante PCR en muestra respiratoria entre el 11 de marzo y el 30 de abril de 2020 en un hospital terciario pediátrico de referencia de Barcelona (España), a los que se hubiera practicado posteriormente un nuevo estudio para comprobar la negativización de la PCR en aspirado nasofaríngeo. Dicho estudio se realizó a pacientes con necesidad de asistencia seriada en hospitales de día, procedimientos, hospitalizaciones programadas, etc. Para estos controles clínicos y de negativización, y pos357 CARTAS CIENTÍFICAS Tabla 1 Datos de negativización de la PCR a SARS-CoV-2 en función de distintas variables Total de pacientes Grupos de pacientes Número..
DOI record: { "DOI": "10.1016/j.anpedi.2021.01.006", "ISSN": [ "1695-4033" ], "URL": "http://dx.doi.org/10.1016/j.anpedi.2021.01.006", "alternative-id": [ "S1695403321000126" ], "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Negativización de PCR a SARS-CoV-2 en muestra respiratoria en pacientes con necesidad de asistencia recurrente" }, { "label": "Journal Title", "name": "journaltitle", "value": "Anales de Pediatría" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.anpedi.2021.01.006" }, { "label": "Content Type", "name": "content_type", "value": "simple-article" }, { "label": "Copyright", "name": "copyright", "value": "© 2021 Asociación Española de Pediatría. Published by Elsevier España, S.L.U." } ], "author": [ { "affiliation": [], "family": "Bassets-Bosch", "given": "Alba", "sequence": "first" }, { "affiliation": [], "family": "Raya-Muñoz", "given": "Judith", "sequence": "additional" }, { "affiliation": [], "family": "Wörner-Tomasa", "given": "Núria", "sequence": "additional" }, { "affiliation": [], "family": "Melendo-Pérez", "given": "Susana", "sequence": "additional" }, { "affiliation": [], "family": "González-Peris", "given": "Sebastià", "sequence": "additional" } ], "container-title": "Anales de Pediatría", "container-title-short": "Anales de Pediatría", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.es", "elsevier.es", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2021, 1, 27 ] ], "date-time": "2021-01-27T12:55:37Z", "timestamp": 1611752137000 }, "deposited": { "date-parts": [ [ 2022, 4, 25 ] ], "date-time": "2022-04-25T22:12:38Z", "timestamp": 1650924758000 }, "indexed": { "date-parts": [ [ 2022, 4, 25 ] ], "date-time": "2022-04-25T22:41:09Z", "timestamp": 1650926469644 }, "is-referenced-by-count": 0, "issue": "4", "issued": { "date-parts": [ [ 2022, 4 ] ] }, "journal-issue": { "issue": "4", "published-print": { "date-parts": [ [ 2022, 4 ] ] } }, "language": "es", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 4, 1 ] ], "date-time": "2022-04-01T00:00:00Z", "timestamp": 1648771200000 } }, { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 1, 27 ] ], "date-time": "2021-01-27T00:00:00Z", "timestamp": 1611705600000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S1695403321000126?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S1695403321000126?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "357-359", "prefix": "10.1016", "published": { "date-parts": [ [ 2022, 4 ] ] }, "published-print": { "date-parts": [ [ 2022, 4 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1136/bmj.m1443", "article-title": "Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study", "author": "Zheng", "doi-asserted-by": "crossref", "first-page": "m1443", "journal-title": "BMJ.", "key": "10.1016/j.anpedi.2021.01.006_bib0030", "volume": "369", "year": "2020" }, { "DOI": "10.1093/cid/ciaa351", "article-title": "Factors associated with prolonged viral RNA shedding in patients with Coronavirus Disease 2019 (COVID-19)", "author": "Xu", "doi-asserted-by": "crossref", "first-page": "799", "journal-title": "Clin Infect Dis.", "key": "10.1016/j.anpedi.2021.01.006_bib0035", "volume": "71", "year": "2020" }, { "DOI": "10.1097/INF.0000000000002814", "article-title": "Duration of respiratory and gastrointestinal viral shedding in children with SARS-CoV-2: A systematic review and synthesis of data", "author": "Xu", "doi-asserted-by": "crossref", "first-page": "e249", "journal-title": "Pediatr Infect Dis J.", "key": "10.1016/j.anpedi.2021.01.006_bib0040", "volume": "39", "year": "2020" }, { "DOI": "10.1093/cid/ciaa619", "article-title": "To interpret the SARS-Cov-2 test consider the cycle threshold value", "author": "Tom", "doi-asserted-by": "crossref", "first-page": "2252", "journal-title": "Clin Infect Dis.", "key": "10.1016/j.anpedi.2021.01.006_bib0045", "volume": "71", "year": "2020" }, { "key": "10.1016/j.anpedi.2021.01.006_bib0050", "unstructured": "Centers for Disease Control and Prevention. Symptom-based strategy to discontinue isolation for persons with COVID-19 [actualizado 19 Oct 2020]. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html" } ], "reference-count": 5, "references-count": 5, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S1695403321000126" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pediatrics, Perinatology and Child Health" ], "subtitle": [], "title": "Negativización de PCR a SARS-CoV-2 en muestra respiratoria en pacientes con necesidad de asistencia recurrente", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "volume": "96" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit